A pilot study using nabilone for symptomatic treatment in Huntington's disease.
Identifieur interne : 001B27 ( PubMed/Corpus ); précédent : 001B26; suivant : 001B28A pilot study using nabilone for symptomatic treatment in Huntington's disease.
Auteurs : Adrienne Curtis ; Ian Mitchell ; Smitaa Patel ; Natalie Ives ; Hugh RickardsSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Adult, Aged, Anti-Anxiety Agents (therapeutic use), Behavioral Symptoms (drug therapy), Behavioral Symptoms (etiology), Cognition Disorders (drug therapy), Cognition Disorders (etiology), Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Dronabinol (analogs & derivatives), Dronabinol (therapeutic use), Female, Humans, Huntington Disease (complications), Huntington Disease (drug therapy), Male, Middle Aged, Neuropsychological Tests, Outcome Assessment (Health Care), Pilot Projects.
- MESH :
- chemical , analogs & derivatives : Dronabinol.
- chemical , therapeutic use : Anti-Anxiety Agents, Dronabinol.
- complications : Huntington Disease.
- drug therapy : Behavioral Symptoms, Cognition Disorders, Huntington Disease.
- etiology : Behavioral Symptoms, Cognition Disorders.
- Adult, Aged, Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Outcome Assessment (Health Care), Pilot Projects.
Abstract
Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.
DOI: 10.1002/mds.22809
PubMed: 19845035
Links to Exploration step
pubmed:19845035Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease.</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation><nlm:affiliation>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham, United Kingdom. ade@rcare.co.uk</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="doi">10.1002/mds.22809</idno>
<idno type="RBID">pubmed:19845035</idno>
<idno type="pmid">19845035</idno>
<idno type="wicri:Area/PubMed/Corpus">001B27</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease.</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation><nlm:affiliation>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham, United Kingdom. ade@rcare.co.uk</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anti-Anxiety Agents (therapeutic use)</term>
<term>Behavioral Symptoms (drug therapy)</term>
<term>Behavioral Symptoms (etiology)</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognition Disorders (etiology)</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dronabinol (analogs & derivatives)</term>
<term>Dronabinol (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Huntington Disease (complications)</term>
<term>Huntington Disease (drug therapy)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Outcome Assessment (Health Care)</term>
<term>Pilot Projects</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term>
<term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
<term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Outcome Assessment (Health Care)</term>
<term>Pilot Projects</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19845035</PMID>
<DateCreated><Year>2009</Year>
<Month>11</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>02</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>24</Volume>
<Issue>15</Issue>
<PubDate><Year>2009</Year>
<Month>Nov</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>A pilot study using nabilone for symptomatic treatment in Huntington's disease.</ArticleTitle>
<Pagination><MedlinePgn>2254-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22809</ELocationID>
<Abstract><AbstractText>Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Curtis</LastName>
<ForeName>Adrienne</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham, United Kingdom. ade@rcare.co.uk</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mitchell</LastName>
<ForeName>Ian</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Patel</LastName>
<ForeName>Smitaa</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ives</LastName>
<ForeName>Natalie</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rickards</LastName>
<ForeName>Hugh</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2N4O9L084N</RegistryNumber>
<NameOfSubstance UI="C011941">nabilone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7J8897W37S</RegistryNumber>
<NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D014151">Anti-Anxiety Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001526">Behavioral Symptoms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004185">Disability Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013759">Dronabinol</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006816">Huntington Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D017063">Outcome Assessment (Health Care)</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>2</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.22809</ArticleId>
<ArticleId IdType="pubmed">19845035</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001B27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:19845035 |texte= A pilot study using nabilone for symptomatic treatment in Huntington's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19845035" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |